Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “Administration, Oral”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

66 records · Page 4
All sourcesNASA NTRSDOE OSTI
NASA NTRS2011

Summary Report for National Aeronautics Space Administration (NASA) and Centro Para Prevencao da Poluicao (C3P) 2011 International Workshop on Environment and Alternative Energy

The C3P &. NASA International Workshop on Environment and Alternative Energy was held on November 15-18, 2011 at the European Space Agency (ESA)'s Research and Technology Centre (ESTEC) in Noordwijk, The Netherlands. The theme of the workshop was "Global Collaboration in Environmental and Alternative Energy Strategies". The workshop was held at ESTEC's conference center. More than 110 individuals from eleven countries attended the workshop. For the first time since the inception of NASA-C3P workshops, a full day was dedicated to a student session. Fifteen students from around the globe gave oral presentations along with poster displays relating to the latest technologies in environmental and alternative energy strategies. Judges from NASA, C3P and ESA awarded plaques to the top three students. In addition to the students, thirty eight U.S. and international subject matter experts presented on the following general environmental-related topics: (1) Hazardous materials management and substitution in support of space operations (2) Emerging renewable and alternative energy technologies (3) Sustainable development and redevelopment (4) Remediation technologies and strategies The workshop also included a panel discussion on the topic of the challenges of operating installations across borders. Throughout the workshop, attendees heard about the scope of environmental and energy challenges that industry and governments face. They heard about technologies for increasing energy efficiency and increasing use of renewable energy. They learned about ways companies and government agencies are using materials, processes, goods and services in a manner more respectful with the environment and in compliance with health and safety rules. The concept of partnerships and their inherent benefits was evidenced throughout the workshop. Partnering is a key aspect of sustainability because sustainable development is complicated. Through formal presentations and side discussions, attendees commented on the need for continued exploration of joint projects of mutual interest.

Greene, Brian↗
NASA NTRS1991

Noninvasive Ph-telemetric Measurement of Gastrointestinal Function

The purpose of this study was to gain experience with and validate the Heidelberg pH-telemetric methodology in order to determine if the pH-telemetric methodology would be a useful noninvasive measure of gastrointestinal transit time for future ground-based and in-flight drug evaluation studies. The Heidelberg pH metering system is a noninvasive, nonradioactive telemetric system that, following oral ingestion, continuously measures intraluminal pH of the stomach, duodenum, small bowel, ileocecal junction, and large bowel. Gastrointestinal motility profiles were obtained in normal volunteers using the lactulose breath-hydrogen and Heidelberg pH metering techniques. All profiles were obtained in the morning after an overnight fast. Heidelberg pH profiles were obtained in the fasting and fed states; lactulose breath-hydrogen profiles were obtained after a standard breakfast. Mouth-to-cecum transit time was measured as the interval from administration of lactulose (30 ml; 20 g) to a sustained increase in breath-hydrogen of 10 ppm or more. Gastric emptying time was measured as the interval from the administration of the Heidelberg capsule to a sustained increase in pH of three units or more.

Tietze, Karen J.↗
DOE OSTI2025

Performance Comparisons for Artificially Propagated and Wild Pacific Lamprey Juveniles and Larvae

ABSTRACT Artificially propagated Pacific lamprey ( Entosphenus tridentatus ) are produced for restoration and for use in dam passage studies to reduce the demand for wild fish. Such uses require that animals are representative of their wild counterparts. Previous work indicated that this is true for Pacific lamprey larvae and juveniles reared in the hatchery with respect to the length of sustained swimming. However, more subtle differences in behaviour and performance that lamprey need to survive have not been assessed. In this study, artificially propagated and wild fish were compared in laboratory tests under no‐flow conditions to examine light avoidance, burrowing speed, burst swim speed, volitional routine swim speed and time to come to rest. Most larvae burrowed in less than a minute, and we found highly significant differences ( p < 0.001) between artificially propagated and wild larvae burrowing times, a critical escape behaviour. This could have implications for studies of larval entrainment at irrigation diversion canals or in turbine boils at dams. Interestingly, all of the wild juveniles tested came to rest quickly after introduction to the chamber (1.5 min), while artificially propagated lamprey swam robotically near the surface and 48% did not come to rest in the first 10 min (median time to rest = 9.5 min). In contrast, wild juveniles quickly (median = 1.47 min) sought areas near the tank bottom and attached strongly with their oral disc. Such behavioural differences could have important survival consequences for artificially propagated lamprey as they approach turbine intakes, bypass screens and irrigation diversion headgates. This study highlights the need to conduct behavioural assays that examine subtleties of fish behaviour that can be missed with traditional swim tunnel comparisons.

Frick, Kinsey [Fish Ecology Division, Northwest Fi↗
NASA NTRS2007

Relative Bioavailability of Scopolamine Dosage Forms and Interaction with Dextroamphetamine

The NASA Reduced Gravity Office (RGO) uses scopolamine (SCOP) and in combination with dextoamphetamine (DEX) to manage motion sickness symptoms during parabolic flights. The medications are dispensed as custom dosage forms as gelatin capsules. Anecdotal evidence of efficacy suggests that these formulations are unreliable and less efficacious for the treatment of motion sickness. We estimated bioavailability of four different oral formulations used by NASA for the treatment of motion sickness. Twelve healthy, non-smoking subjects between 21and 48 years of age received four treatments on separate days in a randomized fashion; the treatments were 0.8 mg SCOP alone as tablet, 0.8 mg SCOP alone in gel cap, 0.8 mg SCOP and 10 mg DEX as tablets, and 0.8 mg SCOP and 10 mg DEX in gel cap. After each treatment, blood, saliva, and urine samples were collected at scheduled time intervals for 24 h after dosing. Bioavailability and pharmacokinetic parameters were calculated and compared using ANOVA. After administration of SCOP tablets alone, maximum concentration (C(sub max)) and time for maximum concentration (t(sub max)) were 0.26 plus or minus 0.04 ng/mL and 0.71 plus or minus 0.02 h, respectively; volume of distribution, and clearance were 47.6 plus or minus 4.72 L/kg and 23.0 plus or minus 4.58 L/h/kg, respectively. SCOP t(sub max) after administration as gelcaps was significantly longer than that with tablets (1.04 h, p less than 0.05), but no significant differences in other pharmacokinetic parameters of SCOP were observed between the two dosage forms. When coadministered with DEX, the area underneath the concentration versus time curve (AUC) of SCOP was significantly reduced to 0.61 plus or minus 0.09 and 0.64 plus or minus 0.11 ng (raised dot) h/mL after administration as a tablet or gelcap formulation, respectively; SCOP C(sub max) was lower after coadministration with DEX, this difference, however, was not statistically significant. Delayed absorption with gelcaps coupled with reduced bioavailability with DEX coadministration may have resulted in the observed treatment failure with some of these formulations. This could result from failure to reach minimum effective concentrations after treatment with gelcap formulations before parabolic flights. A new nomogram for dosing is proposed for treatment with SCOP gelcaps or SCOP-DEX combination.

Boyd, Jason L.↗
NASA NTRS1972

ERISTAR: Earth Resources Information Storage, Transformation, Analysis, and Retrieval administrative report

The 1972 Systems Engineering program at Marshall Space Flight Center where 15 participants representing 15 U.S. universities, 1 NASA/MSFC employee, and another specially assigned faculty member, participated in an 11-week program is discussed. The Fellows became acquainted with the philosophy of systems engineering, and as a training exercise, used this approach to produce a conceptional design for an Earth Resources Information Storage, Transformation, Analysis, and Retrieval System. The program was conducted in three phases; approximately 3 weeks were devoted to seminars, tours, and other presentations to subject the participants to technical and other aspects of the information management problem. The second phase, 5 weeks in length, consisted of evaluating alternative solutions to problems, effecting initial trade-offs and performing preliminary design studies and analyses. The last 3 weeks were occupied with final trade-off sessions, final design analyses and preparation of a final report and oral presentation.

Vachon, R. I.↗
DOE OSTI2025

Preliminary Evidence for Sex-Specific Trends in Probiotic Modulation of Gut Saccharibacteria in Familial Mediterranean Fever Patients: Effects of Lactobacillus acidophilus INMIA 9602 Er 317/402 and Escherichia coli M-17

Candidate Phyla Radiation bacteria are emerging members of the human microbiota, particularly in oral and gut environments. Saccharibacteria were previously identified in the gut microbiota of healthy individuals and women diagnosed with familial Mediterranean fever (FMF), a monogenic autoinflammatory disorder prevalent in the eastern Mediterranean region, including Armenia. This study aimed to assess the prevalence and diversity of Saccharibacteria spp. and its basebiont Schaalia odontolytica in FMF patients, explore gender differences, and evaluate the modulation potential of two locally produced probiotics: Lactobacillus acidophilus INMIA9602 Er317/402 (Narine®, VITAMAX-E, Yerevan, Armenia) and Escherichia coli M-17 (Colibacteron®, VITAMAX-E, Yerevan, Armenia). The abundance and behavior of saccharibacteria and S. odontolytica appear to vary depending on health status and sex. Placebo administration caused both quantitative and qualitative shifts, suggesting a possible interaction between Candidatus saccharibacteria spp. and Schaalia odontolytica, though the underlying biological significance remains to be clarified. Narine administration appeared to increase the abundance of Candidatus saccharibacteria operational taxonomic units (OTUs) in FMF women and S. odontolytica OTUs in FMF men, whereas Colibacteron selectively decreased certain OTUs, predominantly in FMF women. These findings underscore the need to further investigate saccharibacteria’s role in systemic inflammation and probiotic-mediated modulation of the gut microbiota.

Biochemistry & Molecular Biology↗
NASA NTRS1997

Mars Telescopic Observations Workshop II

Mars Telescopic Observations Workshop E convened in Tucson, Arizona, in October 1997 by popular demand slightly over two years following the first successful Mars Telescopic Observations Workshop, held in Ithaca, New York, in August 1995. Experts on Mars from the United Kingdom, Japan, Germany, and the United States were present. Twenty-eight oral presentations were made and generous time allotted for useful discussions among participants. The goals of the workshop were to (1) summarize active groundbased observing programs and evaluate them in the context of current and future space missions to Mars, (2) discuss new technologies and instrumentation in the context of changing emphasis of observations and theory useful for groundbased observing, and (3) more fully understand capabilities of current and planned Mars missions to better judge which groundbased observations are and will continue to be of importance to our overall Mars program. In addition, the exciting new discoveries presented from the Pathfinder experiments and the progress report from the Mars Global Surveyor infused the participants with satisfaction for the successes achieved in the early stages of these missions. Just as exciting was the enthusiasm for new groundbased programs designed to address new challenges resulting from mission science results. We would like to thank the National Aeronautics and Space Administration as well as Dr. David Black, director of the Lunar and Planetary Institute, and the staff of the Institute's Publications and Program Services Department for providing logistical, administrative, and publication support services for this workshop.

Sprague, A. L.↗
NASA NTRS2000

Microgravity as a novel environmental signal affecting Salmonella enterica serovar Typhimurium virulence

The effects of spaceflight on the infectious disease process have only been studied at the level of the host immune response and indicate a blunting of the immune mechanism in humans and animals. Accordingly, it is necessary to assess potential changes in microbial virulence associated with spaceflight which may impact the probability of in-flight infectious disease. In this study, we investigated the effect of altered gravitational vectors on Salmonella virulence in mice. Salmonella enterica serovar Typhimurium grown under modeled microgravity (MMG) were more virulent and were recovered in higher numbers from the murine spleen and liver following oral infection compared to organisms grown under normal gravity. Furthermore, MMG-grown salmonellae were more resistant to acid stress and macrophage killing and exhibited significant differences in protein synthesis than did normal-gravity-grown cells. Our results indicate that the environment created by simulated microgravity represents a novel environmental regulatory factor of Salmonella virulence.

NASA Discipline Environmental Health↗
NASA NTRS2014

Are Medications Involved in Vision and Intracrancial Pressure Changes Seen in Spaceflight?

The Food and Drug Association Adverse Event Reports (FDA AER) from 2009-2011 were used to create a database from millions of known and suspected medication-related adverse events among the general public. Vision changes, sometimes associated with intracranial pressure changes (VIIP), have been noted in some long duration crewmembers. Changes in vision and blood pressure (which can subsequently affect intracranial pressure) are fairly common side effects of medications. The purpose of this study was to explore the possibility of medication involvement in crew VIIP symptoms. Reports of suspected medication-related adverse events may be filed with the Food and Drug Administration (FDA) by medical professionals or consumers. Quarterly compilations of these reports are available for public download. Adverse Event Reporting System (AERS) reports from 1/1/2009- 6/30/2012 were downloaded and compiled into a searchable database for this study. Reports involving individuals under the age of 18 and older than 65 were excluded from this analysis. Case reports involving chronic diseases such as cancer, diabetes, multiple sclerosis and other serious conditions were also excluded. A scan of the medical literature for medication-related VIIP-like adverse events was used to create a list of suspect medications. These medications, as well as certain medications used frequently by ISS crew, were used to query the database. Queries for use of suspected medications were run, and the nature of the symptoms reported in those cases were tabulated. Symptoms searched in the FDA AERS were chosen to include the typical symptoms noted in crewmembers with VIIP. Vision symptoms searched were: visual acuity reduced, visual impairment, and vitreous floaters. Pressure changes included: abnormal sensation in eye, intracranial pressure increased, intraocular pressure increased, optic neuritis, optic neuropathy, and papilloedema. Limited demographic information is included with the FDA AERS; relevant data were also sorted by age and sex from each report. RESULTS Steroid-containing oral contraceptives had the highest number of reports associated with vision (n=166) and pressure symptoms (n=54). Corticosteroid-containing medications were also high; prednisone, for example, had 137 reports of vision issues and 79 of pressure issues. Pain relievers were also a medication class with vision and pressure-related adverse events reported. Common over-the-counter medications such as acetaminophen, aspirin and ibuprofen each had multiple reports for both vision and pressure symptoms. Antimicrobial medications ciprofloxacin and diflucan were also associated with a number of vision and pressure-related AERS. Unexpectedly, pseudoephedrine and promethazine were mentioned in fewer than 20 reports each over the 3.5 years of data examined. The FDA AERS represents a wealth of data, but there are several limitations to its use. The data are entered by the public or medical professionals, but are not checked for accuracy or completeness and may even be entered multiple times. The causal relationship between a particular adverse event and a particular medication is not tested. The cases represent a broad spectrum of demographics, occupations, and health histories, and thus do not model the astronaut population well. There is no information on the frequency of use of a medication for comparison purposes; it is not possible to assign a rate for any particular adverse event. Nonetheless, there are compelling trends. Use of corticosteroid-containing medications, pain relievers (even over-the-counter), and oral contraceptives were associated with higher numbers of vision- or intracranial pressure-related adverse events. In general, there were more vision problems than pressure problems reported. Certain medications that were once suspected of playing a role in the crew VIIP syndrome, namely pseudoephedrine and promethazine, were found to have extremely low numbers of VIIP-like AERS in the FDA data. However, crew use of corticosteroid-containing medications and pain relievers may warrant additional investigation

Faust, K. M.↗
NASA NTRS2011

Evapotranspiration as a Regional Climate Priority: Results from a NASA/USDA Workshop

On April 5 to 7, 2011, the National Aeronautics and Space Administration (NASA) and the United States Department of Agriculture-Agricultural Research Service (USDA-ARS) sponsored a Workshop on Evapotranspiration (ET) in Silver Spring Maryland. The workshop was a response to a recommendation in the 2009-2011 GEO (Group on Earth Observations) Work Plan that a workshop on ET should be held to discuss issues related to ET products and services and the potential for incorporating ET activities into the 2012-2015 GEO Work Plan. The workshop had a regional emphasis, although there were several excellent international and global presentations including one on the GEWEX LANDFLUX project. The different scales of these activities suggests that a framework is needed that can accommodate both regional and global ET activities. Despite limitations with the workshop's scheduling, it attracted 76 experts who contributed informative presentations and insightful discussions. The goals of the workshop involved the exchange of information and ideas and the development of plans for providing more visibility for ET issues. Specific objectives included 1) defining the needs and requirements for evapotranspiration data in weather and climate studies, in natural and agro-ecoystem monitoring, and in water resource management; 2) reviewing the methods used to measure and model evapotranspiration; 3) assessing surface and satellite observation systems required to support ET measurement, modeling and evaluation; 4) assessing the feasibility of developing a proposal for a task on evapotranspiration for the 2012-2015 GEO Work Plan, and 5) exploring the level of support and consensus for developing a strategy for establishing evapotranspiration as an Essential Climate Variable (ECV) within the Global Climate Observing System (GCOS) framework The workshop featured a combination of oral presentations and breakout group sessions focused on the above objectives. There were also poster presentations providing opportunities for one-on-one discussions of ET modeling and measurement techniques. Presentations by users of ET data set the tone for the workshop. In the USA at the national and regional levels water rights issues represent a major opportunity for ET applications. ET data play a major role in estimating water loss due to irrigation, the largest cause of consumptive water loss in the USA, particularly in the West. Irrigation requirements are relatively specific since the needs are clearly defined by the geometry and number of the irrigation systems and can be monitored with high resolution satellite data. There was a strong consensus that land surface temperature (LST) at high resolution is critical for monitoring irrigation. State governments have made commitments to more efficient water management in the western US, but they need full access to improved and more timely ET data and applications to implement this plan. Water managers also reported that in spite of the recent development of. new techniques, the procedures used in some of the water balance calculations in some states are out of date and do not take advantage of new observational and data assimilation systems. The development of ET forecasts for water management is also seen as a priority. Although ET forecasts are currently being produced on an experimental basis these predictions could be improved by considering ET as a dynamic prediction variable in models and by increasing the time resolution of these ET predictions.

Lawford, Richard↗
NASA NTRS1998

Bioavailability of intranasal promethazine dosage forms in dogs

Intramuscular promethazine (PMZ) is used aboard the US Space Shuttle to ameliorate symptoms of space motion sickness. Bioavailability after an oral dose of PMZ during space flight is thought to be impaired because of gastrointestinal disturbances associated with weightlessness and space motion sickness. In an attempt to find an alternative dosage form for use in space, we evaluated two intranasal (i.n.) dosage forms of PMZ in dogs for absorption and bioavailability relative to that of an equivalent intramuscular dose. Promethazine (5 mg kg-1) was administered as two intranasal dosage forms and as an intramuscular (i.m.) dose to three dogs in a randomised cross-over design. Serial blood samples were taken and analysed for PMZ concentrations and the absorption and bioavailability of PMZ were calculated for the three dosage forms. PMZ absorption from the carboxymethyl cellulose microsphere i.n. dosage form was more rapid and complete than from the myverol cubic gel formulation or from an i.m. injection. Bioavailability of the microsphere formulation was also greater than that of the gel formulation (AUC 3009 vs 1727 ng h ml-1). The bioavailability of the two i.n. dosage forms (relative to that of the i.m. injection) were 94% (microsphere) and 54% (gel). The i.n. microsphere formulation of PMZ offers great promise as an effective non-invasive alternative for treating space motion sickness due to its rapid absorption and bioavailability equivalent to the i.m. dose.

NASA Center JSC↗
NASA NTRS2007

Pharmacotherapeutics of Intranasal Scopolamine: FDA Regulations and Procedures for Clinical Applications

Space Motion Sickness (SMS) is commonly experienced by astronauts and often requires treatment with medications during the early flight days of a space mission. Bioavailability of oral (PO) SMS medications is often low and highly variable; additionally, physiological changes in a microgravity environment exacerbate variability and decrease bioavailability. These factors prompted NASA to develop an intranasal dosage form of scopolamine (INSCOP) suitable for the treatment of SMS. However, to assure safety and efficacy of treatment in space, NASA physicians prescribe commercially available pharmaceutical products only. Development of a pharmaceutical preparation for clinical use must follow distinct clinical phases of testing, phase I through IV to be exact, before it can be approved by the FDA for approval for clinical use. After a physician sponsored Investigative New Drug (IND) application was approved by the FDA, a phase I clinical trial of INSCOP formulation was completed in normal human subjects and results published. The current project includes three phase II clinical protocols for the assessment of pharmacokinetics and pharmacodynamics (PK/PD), efficacy, and safety of INSCOP. Three clinical protocols that were submitted to FDA to accomplish the project objectives: 1) 002-A, a FDA Phase II dose ranging study with four dose levels between 0.1 and 0.4 mg in 12 subjects to assess PK/PD, 2) 002-B, a phase II clinical efficacy study in eighteen healthy subjects to compare efficacy of 0.2 (low dose) and 0.4 mg (high dose) INSCOP for prophylactic treatment of motion-induces (off-axis vertical rotation) symptoms, and (3) 002-C, a phase II clinical study with twelve subjects to determine bioavailability and pharmacodynamics of two doses (0.2 and 0.4 mg) of INSCOP in simulated microgravity, antiorthostatic bedrest. All regulatory procedures were competed that include certification for Good laboratory Procedures by Theradex , clinical documentation, personnel training, selection of clinical research operations contractor, data capturing and management, and annual reporting of results to FDA were successfully completed. Protocol 002-A was completed and sample and data analysis is currently in progress. Protocol 002-B is currently in progress at Dartmouth Hitchcock Medical Center and Protocol 002-C has been submitted to the FDA and will be implemented at the same contractor site as 002-A. An annual report was filed as required by FDA on the results of Protocol 002-A. Once all the three Phase II protocols are completed, a New Drug Administration application will be filed with FDA for Phase III clinical assessment and approval for marketing of the formulation. A commercial vendor will be identified for this phase. This is critical for making this available for treatment of SMS in astronauts and military personnel on duty. Once approved by FDA, INSCOP can be also used by civilian population for motion sickness associated with recreational travel and other ailments that require treatment with anticholinergic drugs.

Das, H.↗